Insurance coverage for neuropathy cell therapy is inconsistent globally. US insurance does not reimburse. European insurance (Spain, Portugal, Germany) occasionally covers for diabetic neuropathy with significant disability when conventional management (glycaemic control, neuropathic medications) has been exhausted. Explicit pre-authorisation and specialist documentation are required. Most patients are responsible for out-of-pocket costs unless enrolled in sponsored clinical trials.
Neuropathy cell therapy costs €4,000–6,500 depending on delivery method and cell source. Systemic intravenous MSC infusion (€4,500–5,500) is most accessible. Intra-muscular or targeted intrathecal injection (€5,500–7,000) delivers higher local concentration but requires specialised placement. Exosome therapy (€4,000–5,500) is emerging with competitive pricing. Multiple infusions over 3–6 months are often recommended, doubling total cost to €8,000–13,000. Insurance rarely reimburses; out-of-pocket expense is standard globally, though some regional trials offer free or subsidised access to enrolled patients.
Am I a candidate? → · Peripheral Neuropathy: full overview → · Peripheral Neuropathy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка